N/A N=60 Hyperglycemia in Renal Transplantation
Diabetes · End Stage Renal Disease
Primary: Incidence of Poor Graft Function After Kidney Transplant — 13; 22 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=120 Effect of Remote Ischaemic Preconditioning on Renal Function in Patients Undergoing Living Donor Kidney Transplantation
Kidney Diseases · Kidney Failure, Chronic · Kidney Failure
Primary: Plasma Creatine Concentration of the Recipients — 849.5; 878.5; 771.0; 776.5 μmol/l
N/A N=40 Study in Recipients of Renal Transplant Allograft to Evaluate the Impact of Two Immunosuppressive Regimens
End Stage Renal Failure With Renal Transplant
Primary: Change in T Cell & B Cell Generation — 1.05; 0.93; 0.8; 1.12 Mean % of Treg cells in peripheral blood
Phase 4 N=2,037 Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)
End Stage Renal Disease (ESRD) · Chronic Kidney Disease (CKD) · Hemodialysis
Primary: Incidence of Failure on the Composite of Treated Biopsy-proven Acute Rejection (tBPAR) or Estimated Glomerular Filtration Rate (eGFR) < 50 mL/Min/1.73m2. — 489; 456…
Phase 4 N=11 Prospective Pilot Study of Pre-Transplant Thymoglobulin Administration in Living Donor Renal Transplant Recipients
Renal Transplant Rejection · Transplants and Implants
Primary: Composite End Point of Acute Rejection, Graft Loss or Patient Death — 1; 1; 0; 0 participants
Phase 3 N=543 Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
Renal Transplantation
Primary: Percentage of Participants Who Survived With a Graft at 12 Months Post-Transplant — 85.9; 88.0; 84.8 percentage of participants
N/A N=104 IV Insulin Protocol in Diabetes and Renal Transplantation
Kidney Transplantation · Diabetes · Hyperglycemia
Primary: Delayed Graft Function — 8; 12 participants
N/A N=128 An Observational Study on Renal Function in Kidney Transplant Participants on Immunosuppressive Therapy Containing Mycophenolate Mofetil
Kidney Transplantation
Primary: Creatinine Clearance at 1 Month After Transplantation — 65.82 mL/min
Phase 2 N=290 Effects of Inhibiting Early Inflammation in Kidney Transplant Patients
Kidney Transplant
Primary: The Difference Between the Mean eGFR (Modified MDRD) in the Experimental vs. Control Groups. — 52.45; 57.35 mL/min/1.73m2 — p=0.099
Phase 2 N=7 Study of Islet Transplantation in Type 1 Diabetic Kidney Transplant Recipients
Diabetes Mellitus, Type I
Primary: Insulin Independence With Both an HbA1c ≤ 6.5% and no Severe Hypoglycemic Events at 1 Year After the First Islet Transplant or a Reduction in HbA1c of at Least 1 Point…
Phase 3 N=78 REnal Function in Liver Transplantation: Everolimus With Calcineurin Inhibitor (CNI)-Sparing sTrategy
Liver Transplantation
Primary: Renal Function Assessed by Estimated Glomerular Filtartion Rate (eGFR) — 85.50; 80.26 mL/min/1.73m^2 — p=0.3013
Phase 3 N=61 Study Evaluating Sirolimus in Kidney Transplant Recipients
Graft vs Host Disease · Kidney Transplantation
Primary: Mean Creatinine Clearance Rate — 56.800; 53.449 ml/min — p=0.6081
N/A N=50 Perioperative Aminophylline to Improve Early Kidney Function After a Kidney Transplant
Function of Renal Transplant
Primary: Calculated Estimated Glomerular Filtration Rate (eGFR) — 67.39; 80.48 ml/min/1.73m2 — p=0.32
Phase 3 N=203 Preservation of Renal Function in Liver Transplant Recipients With Certican Therapy
Liver Transplantation
Primary: Calculated Glomerular Filtration Rate (cGFR) — 87.9; 84.1 mL/min
Phase 3 N=145 RESCUE Study - Everolimus in Liver Transplantation Recipients With Renal Insufficiency
Liver Transplantation
Primary: Mean Change From Baseline in Cockcroft-Gault Calculated Creatinine Clearance (CrCl) — 0.99; 2.26 mL/min
Phase 2 N=58 Regimen Optimization Study
Kidney Transplantation
Primary: Percentage of Clinically-suspected Biopsy-proven Acute Rejection (CSBPAR) at 6 Months — 7.7; 9.4 Percentage of participants
Phase 2 N=31 Combination Drug Therapy Followed by Single Drug Steroid Free Therapy to Prevent Organ Rejection in Kidney Transplantation
Kidney Transplantation
Primary: The Rate of Allograft Rejection — 0; 0 participants
N/A N=135 Effects of Personalized Physical Rehabilitation in Kidney Transplant Recipients
Kidney Transplant
Primary: Employment Status — 21; 2 Participants
Phase 4 N=26 Panel Reactive Antibody (PRA) Reduction in Sensitized Patients Awaiting Renal Transplantation
End Stage Renal Disease
Primary: The Percent of Sensitized Patients Treated With PRA Reduction Pharmacological Therapy, Including Cytogam, Who Become Cross-match Compatible With Potential Living Donor…
N/A N=2 Combined Bone Marrow and Renal Transplantation for Hematologic Disorders With End Stage Renal Disease
Multiple Myeloma · Amyloidosis
Primary: Number of Participants Without Renal Allograft Rejection at 6 Months Post-transplant — 1 Participants
Phase 3 N=90 Denosumab for Prevention of Osteoporosis in Renal Transplant Recipients
Osteoporosis · Chronic Kidney Disease
Primary: Percent Change in BMD at the Total Lumbar Spine From Baseline to Month 12 — 4.5; -0.3 percent change — p=<0.001
Phase 4 N=57 Belatacept Compared to Tacrolimus in Deceased Donor Renal Transplant Recipients
Implant or Graft; Rejection
Primary: Number of Participants With Delayed Graft Function (DGF) — 12; 15 Participants
Phase 2 N=12 Sirolimus and Thymoglobulin to Prevent Kidney Transplant Rejection
Kidney Failure
Primary: Serum Creatinine Concentration — 112 umol/L
N/A N=24 Conversion to Everolimus From Calcineurin Inhibitor With Mycophenolic Acid: Impact on Long Term Renal Function in Liver Transplantation.
Immunosuppression · Renal Failure
Primary: Renal Function as Measured by 24 Hour Urine Creatinine Clearance — 68.09; 70.75; 68.09; 86.8 mL/min
Phase 2 N=5 Combined Kidney and Bone Marrow Transplantation to Prevent Kidney Transplant Rejection
Kidney Transplantation · Kidney Failure, Chronic
Primary: Number of Participants Successfully Withdrawn Off of Immunosuppressant Medication for 104 Weeks — 3 participants
Phase 2 N=18 A Study in Participants With End-Stage Renal Disease
Kidney Failure, Chronic
Primary: Change From Baseline in PRA — -0.706; -2.176; -1.688; -2.353 percentage of population — p=0.324
Phase 1 N=16 Subcutaneous Abatacept in Renal Transplant Recipients
Kidney Transplant Recipient
Primary: Number of Participants Who Are Compliant With Self-administration — 8; 5; 1 Participants
Phase 2 N=13 A Dose Escalation Study in de Novo Renal Transplantation
Kidney Transplantation
Primary: Number of Participants With Treatment-emergent Adverse Events as Assessed by CTCAE v5.0. — 2; 4; 7; 0 Participants
N/A N=88 HLA-Identical Sibling Renal Transplant Tolerance
Immunosuppression · Kidney Transplantation · Graft Rejection
Primary: The Ability to Withdraw Immunosuppression as Above 24 Months Post-transplant — 6 Participants
Phase 3 N=130 Efficacy Regarding Renal Function of Everolimus in Combination With Specific Standard Immunosuppressive Regimen Lung Transplant Recipients
Lung Transplantation
Primary: Calculated Glomerular Filtration Rate (cGFR) According to Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) at 12 Months — 64.5; 54.6 mL/min — p=<0.0001